ProKidney (PROK) Competitors $2.41 +0.09 (+3.88%) Closing price 04:00 PM EasternExtended Trading$2.39 -0.02 (-0.66%) As of 05:02 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock PROK vs. ARWR, IMVT, ALVO, IBRX, BHC, KYMR, GMTX, KNSA, CPRX, and OGNShould you be buying ProKidney stock or one of its competitors? The main competitors of ProKidney include Arrowhead Pharmaceuticals (ARWR), Immunovant (IMVT), Alvotech (ALVO), ImmunityBio (IBRX), Bausch Health Cos (BHC), Kymera Therapeutics (KYMR), Gemini Therapeutics (GMTX), Kiniksa Pharmaceuticals International (KNSA), Catalyst Pharmaceuticals (CPRX), and Organon & Co. (OGN). These companies are all part of the "pharmaceutical products" industry. ProKidney vs. Its Competitors Arrowhead Pharmaceuticals Immunovant Alvotech ImmunityBio Bausch Health Cos Kymera Therapeutics Gemini Therapeutics Kiniksa Pharmaceuticals International Catalyst Pharmaceuticals Organon & Co. ProKidney (NASDAQ:PROK) and Arrowhead Pharmaceuticals (NASDAQ:ARWR) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, risk, earnings, media sentiment, dividends and valuation. Do analysts rate PROK or ARWR? ProKidney currently has a consensus target price of $6.25, indicating a potential upside of 159.34%. Arrowhead Pharmaceuticals has a consensus target price of $43.14, indicating a potential upside of 102.26%. Given ProKidney's higher probable upside, equities analysts plainly believe ProKidney is more favorable than Arrowhead Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ProKidney 1 Sell rating(s) 2 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.33Arrowhead Pharmaceuticals 0 Sell rating(s) 2 Hold rating(s) 5 Buy rating(s) 2 Strong Buy rating(s) 3.00 Which has more volatility and risk, PROK or ARWR? ProKidney has a beta of 1.76, meaning that its share price is 76% more volatile than the S&P 500. Comparatively, Arrowhead Pharmaceuticals has a beta of 0.94, meaning that its share price is 6% less volatile than the S&P 500. Which has stronger valuation and earnings, PROK or ARWR? ProKidney has higher earnings, but lower revenue than Arrowhead Pharmaceuticals. Arrowhead Pharmaceuticals is trading at a lower price-to-earnings ratio than ProKidney, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioProKidney$80K8,817.59-$61.19M-$0.57-4.23Arrowhead Pharmaceuticals$3.55M830.73-$599.49M-$1.28-16.66 Is PROK or ARWR more profitable? ProKidney's return on equity of 0.00% beat Arrowhead Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets ProKidneyN/A N/A -17.11% Arrowhead Pharmaceuticals N/A -40.91%-11.62% Do insiders and institutionals believe in PROK or ARWR? 51.6% of ProKidney shares are held by institutional investors. Comparatively, 62.6% of Arrowhead Pharmaceuticals shares are held by institutional investors. 41.5% of ProKidney shares are held by company insiders. Comparatively, 4.3% of Arrowhead Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Does the media refer more to PROK or ARWR? In the previous week, Arrowhead Pharmaceuticals had 14 more articles in the media than ProKidney. MarketBeat recorded 20 mentions for Arrowhead Pharmaceuticals and 6 mentions for ProKidney. Arrowhead Pharmaceuticals' average media sentiment score of 0.76 beat ProKidney's score of 0.21 indicating that Arrowhead Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ProKidney 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Arrowhead Pharmaceuticals 11 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryProKidney and Arrowhead Pharmaceuticals tied by winning 8 of the 16 factors compared between the two stocks. Get ProKidney News Delivered to You Automatically Sign up to receive the latest news and ratings for PROK and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PROK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PROK vs. The Competition Export to ExcelMetricProKidneyMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$705.41M$2.80B$5.82B$9.73BDividend YieldN/A1.66%3.84%4.09%P/E Ratio-4.2322.6131.1525.96Price / Sales8,817.59751.87474.77122.97Price / CashN/A173.2237.1558.38Price / Book-0.705.869.116.39Net Income-$61.19M$31.83M$3.26B$265.56M7 Day Performance2.12%1.80%2.12%1.98%1 Month Performance-20.98%4.36%5.13%1.33%1 Year Performance10.55%11.45%31.25%21.15% ProKidney Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PROKProKidney3.7833 of 5 stars$2.41+3.9%$6.25+159.3%-2.9%$705.41M$80K-4.233News CoverageShort Interest ↓ARWRArrowhead Pharmaceuticals3.7466 of 5 stars$19.99+12.3%$43.14+115.8%-17.8%$2.76B$3.55M-15.62400IMVTImmunovant2.9655 of 5 stars$15.89+4.5%$35.20+121.5%-54.3%$2.72BN/A-5.58120Positive NewsALVOAlvotech2.4485 of 5 stars$8.96+3.6%$14.00+56.3%-31.7%$2.70B$491.98M24.221,032News CoverageShort Interest ↓High Trading VolumeIBRXImmunityBio2.5712 of 5 stars$2.82+14.2%$12.25+334.4%-49.1%$2.67B$14.74M-5.87590High Trading VolumeBHCBausch Health Cos4.3441 of 5 stars$7.18+2.5%$9.00+25.4%+28.7%$2.66B$9.86B27.6020,700Analyst RevisionKYMRKymera Therapeutics3.0894 of 5 stars$40.73+2.2%$59.11+45.1%-12.3%$2.65B$47.07M-11.74170GMTXGemini TherapeuticsN/A$59.03+0.8%N/A+17.6%$2.56BN/A-59.0330KNSAKiniksa Pharmaceuticals International2.4832 of 5 stars$33.65+2.7%$41.17+22.3%+27.1%$2.49B$423.24M841.46220Insider TradeCPRXCatalyst Pharmaceuticals4.9192 of 5 stars$20.19-0.7%$33.20+64.4%+0.4%$2.47B$558.50M12.2480Positive NewsAnalyst DowngradeOGNOrganon & Co.4.7554 of 5 stars$9.34+3.2%$18.00+92.7%-55.9%$2.43B$6.40B3.474,000Positive News Related Companies and Tools Related Companies ARWR Alternatives IMVT Alternatives ALVO Alternatives IBRX Alternatives BHC Alternatives KYMR Alternatives GMTX Alternatives KNSA Alternatives CPRX Alternatives OGN Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PROK) was last updated on 8/22/2025 by MarketBeat.com Staff From Our PartnersGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredBREAKING: The House just passed 3 pro-crypto bills!The “top secret” DeFi play Our #1 Coin Report reveals which protocol is building this institutional bridge...Crypto 101 Media | Sponsored“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | SponsoredTax Drain Deadline: Protect Your Wealth Before September 15thOn September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | SponsoredA grave, grave error.Nvidia just shattered records—hitting $4 trillion in valuation faster than any company in history. But one ...Porter & Company | SponsoredCould This Be the End of Retirement Worries?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ProKidney Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share ProKidney With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access